Daiichi Sankyo
Tokyo, JapanWebsite
A global pharmaceutical company with a massive R&D footprint, focusing heavily on oncology and innovative antibody-drug conjugates (ADCs).
2open roles
Loading company information...
A global pharmaceutical company with a massive R&D footprint, focusing heavily on oncology and innovative antibody-drug conjugates (ADCs).
Company context
Daiichi Sankyo prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
Daiichi Sankyo is a global pharmaceutical leader headquartered in Tokyo, Japan, formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company. The organization has established itself as a powerhouse in oncology, particularly through its proprietary DXd-ADC (Antibody Drug Conjugate) technology. By combining over a century of scientific heritage with modern innovation, the company focuses on delivering life-changing therapies for patients worldwide, with a significant presence in over 30 countries and major regional hubs in the United States and Europe.
To become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society by creating life-changing solutions for patients through the union of cutting-edge science and technology.
Founded
2005
Headquarters
Tokyo, Japan
Employees
15,000 - 20,000
Industry
Pharmaceuticals and Biotechnology
Strong focus on innovation and cutting-edge scientific research.
Competitive compensation and benefits packages typical of large pharma.
Global career development opportunities across multiple continents.
Large corporate structure can lead to slower decision-making processes.
Revenue
1.6 trillion JPY (FY2023)
Funding
Publicly Traded (TYO: 4568)
CEO
Sunao Manabe
High pressure environment due to the fast-paced nature of oncology drug development.
Complex internal bureaucracy inherent in a multinational pharmaceutical entity.